Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma

Clin Cancer Res. 2015 Jun 15;21(12):2677-83. doi: 10.1158/1078-0432.CCR-14-3180. Epub 2015 Mar 19.

Abstract

Smoothened inhibitors represent the first class of targeted drugs approved for use in advanced and metastatic basal cell carcinoma. For many patients with limited treatment options, this drug class has led to significant clinical improvements, but is not without side effects. In this review, we outline the basic mechanism of smoothened inhibitors and the most commonly observed cutaneous and extracutaneous side effects. We also highlight possible mechanisms for these adverse events and current management strategies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / pharmacology
  • Carcinoma, Basal Cell / complications*
  • Carcinoma, Basal Cell / drug therapy
  • Carcinoma, Basal Cell / pathology*
  • Disease Management
  • Drug-Related Side Effects and Adverse Reactions / diagnosis*
  • Drug-Related Side Effects and Adverse Reactions / therapy*
  • Humans
  • Neoplasm Staging
  • Receptors, G-Protein-Coupled / antagonists & inhibitors*
  • Skin Diseases / diagnosis
  • Skin Diseases / etiology
  • Skin Diseases / therapy
  • Smoothened Receptor

Substances

  • Antineoplastic Agents
  • Receptors, G-Protein-Coupled
  • SMO protein, human
  • Smoothened Receptor